M&A Deal Summary |
|
---|---|
Date | 2013-11-07 |
Target | Santarus |
Sector | Life Science |
Buyer(s) | Salix Pharmaceuticals |
Deal Type | Add-on Acquisition |
Deal Value | 2.6B USD |
Advisor(s) | Stifel, Nicolaus & Co., Inc. (Financial) Latham & Watkins (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 1989 |
Sector | Life Science |
Revenue | 933M USD (2013) |
Salix Pharmaceuticals Ltd. is a developer and marketer of prescription pharmaceutical products and medical devices for the prevention and treatment of gastrointestinal diseases. Salix's strategy is to in-license late-stage or marketed proprietary therapeutic products, complete any required development and regulatory submission of these products, and market them through Salix's gastroenterology specialty sales and marketing team.
DEAL STATS | # |
---|---|
Overall | 4 of 4 |
Sector (Life Science) | 2 of 2 |
Type (Add-on Acquisition) | 3 of 3 |
State (California) | 1 of 1 |
Country (United States) | 3 of 3 |
Year (2013) | 1 of 1 |
Size (of disclosed) | 1 of 1 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2011-11-08 |
Oceana Therapeutics
Edison, New Jersey, United States Oceana Therapeutics, Inc., a privately-held provider of gastroenterology and urology therapeutics. |
Buy | - |